Thanks Third, for your assessment of these new platforms, and their potential challenges to overcome to be successful. Of course 15 years ago. there was lots of doubt about the likelihood of small molecule CFTR potentiators or correctors as well. If the Vertex HBE in vitro assays show successful production of CFTR using gene editing or mRNA insertion techniques in treated CF HBE cells, I would hope that nuclease degradation would not be too much different in the human body. I look forward to hearing about these test results in the coming years to see if these technologies can possibly deliver on their promise.
David Altshuler, VRTX CSO, announced VRTX is partnering with yet another company with a novel cutting edge approach to treating CF. So now VRTX has commercial rights to Pharion's EnAc drug, CRSPR's technology, and Moderna's mRNA platform to test it's ability to improve CFTR function. Judging from VRTX stock price reaction, the analysts apparently like the news.